What is Citius Pharmaceuticals, Inc. (CTXR)?

Citius Pharmaceuticals, Inc. (CTXR) is a stock in the Healthcare sector, Biotechnology industry. View full analysis on Stocks360.

What is the current price of CTXR?

The current price of CTXR is $0.54. Prices are updated in real time on Stocks360.

What is CTXR's price-to-earnings (PE) ratio?

CTXR's trailing twelve-month PE ratio is -0.26, based on current price and earnings per share data available on Stocks360.

What is CTXR's market capitalization?

CTXR's market capitalization is $14,854,586.00, placing it in the small-cap tier.

Citius Pharmaceuticals, Inc. (CTXR)

Stock analysis · NASDAQ · Healthcare · Biotechnology

$0.54

Market Cap

$14.85M

PE (TTM)

-0.26

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

1.00

Day Range

$0.48 – $0.55

52-wk Range

$0.37 – $1.64

Avg Volume

N/A

Volume

201.08K

Citius Pharmaceuticals, Inc. (CTXR) is a publicly traded company in the Healthcare sector. Latest price: $0.54. Market cap $14.85M. Trailing PE -0.26. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

1-Year Price

2025-10-29 · $1.51 2026-10-28 · $0.54 (-64.17%)

Earnings

Most Recent

Aug 14, 2026

EPS $-0.34 vs est. $-0.36

Beat by $0.02

Next Earnings

Dec 22, 2026

EPS estimate $-0.41

Proprietary Signals

Signal snapshot temporarily unavailable.

About Citius Pharmaceuticals, Inc.

Citius Pharmaceuticals, Inc. operates as a specialized pharmaceutical firm concentrating on the development and market introduction of critical care products. Its efforts are particularly directed towards anti-infective treatments supporting cancer care, various prescription medications, and pioneering mesenchymal stem cell therapies. Mino-Wrap: A novel liquifying gel-based wrap aimed at minimizing infections associated with tissue expanders following breast reconstructive procedures. Halo-Lido: A topical formulation that blends a corticosteroid with lidocaine, intended to deliver both anti-inflammatory and numbing relief to individuals suffering from hemorrhoids. NoveCite: A mesenchymal stem cell therapy currently under development for treating acute respiratory distress syndrome (ARDS). I/ONTAK: An engineered fusion protein, combining IL-2 and diphtheria toxin, purposed for the treatment of patients experiencing persistent or recurrent cutaneous T-cell lymphoma. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	-0.26×
P/S (TTM)	2.09×
P/B	0.21×
P/FCF (TTM)	-0.43×
EV / EBITDA	-0.09×
EV / Sales	0.71×
Earnings Yield	-326.79%
Free Cash Flow Yield	-234.72%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	$5.02M
Revenue (TTM)	$7.11M
Net Income (TTM)	-$48.54M
Free Cash Flow (TTM)	-$42.52M
Net Debt	-$9.83M
Working Capital	-$8.32M
Gross Margin	19.97%
Operating Margin	-863.92%
Net Margin	-651.27%
Return on Equity	-67.15%
Return on Invested Capital	-67.62%